Phase I study of AG-120, an IDH1 mutant enzyme inhibitor: Results from the cholangiocarcinoma dose escalation and expansion cohorts.

被引：0
|
作者：
Lowery, Maeve Aine
Abou-Alfa, Ghassan K.
Burris, Howard A.
Janku, Filip
Shroff, Rachna T.
Cleary, James M.
Azad, Nilofer Saba
Goyal, Lipika
Maher, Elizabeth A.
Gore, Lia
Hollebecque, Antoine
Beeram, Muralidhar
Trent, Jonathan C.
Jiang, Liewen
Ishii, Yuko
Auer, Julia
Gliser, Camelia
Agresta, Samuel V.
Pandya, Shuchi Sumant
Zhu, Andrew X.
机构：
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2017年 / 35卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
4013
引用
收藏
页数：6
相关论文
共 50 条
  • [31] Mutant IDH1 inhibitor ivosidenib (IVO; AG-120) in combination with azacitidine (AZA) for newly diagnosed acute myeloid leukemia (ND AML).
    Dinardo, Courtney Denton
    Stein, Anthony Selwyn
    Stein, Eytan M.
    Fathi, Amir Tahmasb
    Frankfurt, Olga
    Schuh, Andre C.
    Martinelli, Giovanni
    Patel, Prapti Arvind
    Raffoux, Emmanuel
    Tan, Peter
    Zeidan, Amer Methqal
    de Botton, Stephane
    Kantarjian, Hagop M.
    Stone, Richard M.
    Lam, Du Hung
    Gong, Jing
    Zhang, Vickie
    Winkler, Thomas
    Wu, Bin
    Vyas, Paresh
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [32] Ivosidenib (IVO; AG-120) in IDH1-Mutant Newly- Diagnosed Acute Myeloid Leukemia (ND AML): Updated Results from a Phase 1 Study
    DiNardo, Courtney D.
    Roboz, Gail J.
    Stein, Eytan M.
    de Botton, Stephane
    Mims, Alice S.
    Prince, Gabrielle T.
    Altman, Jessica K.
    Arellano, Martha L.
    Donnellan, Will
    Erba, Harry P.
    Mannis, Gabriel N.
    Pollyea, Daniel A.
    Stein, Anthony S.
    Uy, Geoffrey L.
    Watts, Justin M.
    Fathi, Amir T.
    Kantarjian, Hagop M.
    Tallman, Martin S.
    Choe, Sung
    Dai, David
    Fan, Bin
    Wang, Hongfang
    Zhang, Vickie
    Yen, Katharine E.
    Kapsalis, Stephanie M.
    Hickman, Denice
    Liu, Hua
    Agresta, Samuel V.
    Wu, Bin
    Attar, Eyal C.
    Stone, Richard M.
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2019, 19 : S220 - S220
  • [33] Evaluation of drug-drug interaction of itraconazole and ivosidenib (AG-120), an oral, potent, targeted, small molecule inhibitor of mutant IDH1, in healthy subjects
    Fan, B.
    Prakash, C.
    Liu, H.
    Liu, G.
    Korth, C.
    Yang, H.
    Dai, D.
    EUROPEAN JOURNAL OF CANCER, 2018, 103 : E40 - E41
  • [34] TRX-E-002-1 in treatment-refractory ovarian cancer: Final phase 1 study results from the dose-escalation and dose-expansion cohorts.
    Coward, Jermaine
    Kichenadasse, Ganessan
    Harnett, Paul
    Moore, Kathleen
    Barve, Minal
    Garner, James
    Lopresti, Mary
    Dizon, Don S.
    CANCER RESEARCH, 2021, 81 (13)
  • [35] Phase I study of a brain penetrant mutant IDH1 inhibitor DS-1001b in patients with recurrent or progressive IDH1 mutant gliomas.
    Natsume, Atsushi
    Wakabayashi, Toshihiko
    Miyakita, Yasuji
    Narita, Yoshitaka
    Mineharu, Yohei
    Arakawa, Yoshiki
    Yamasaki, Fumiyuki
    Sugiyama, Kazuhiko
    Hata, Nobuhiro
    Muragaki, Yoshihiro
    Nishikawa, Ryo
    Shinojima, Naoki
    Kumabe, Toshihiro
    Saito, Ryuta
    Ito, Kazumi
    Tachibana, Masaya
    Kakurai, Yasuyuki
    Nishijima, Soichiro
    Tsubouchi, Hiroshi
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [36] Safety and Clinical Activity of Mutant IDH1 Inhibitor IVOSIDENIB (IVO; AG-120) In Combination with AZACITIDINE (AZA) for Newly Diagnosed Acute Myeloid Leukemia (ND AML)
    DiNardo, C.
    Stein, A.
    Stein, E.
    Fathi, A.
    Frankfurt, O.
    Schuh, A.
    Doehner, H.
    Martinelli, G.
    Patel, P.
    Raffoux, E.
    Tan, P.
    Zeidan, A.
    de Botton, S.
    Kantarjian, H.
    Stone, R.
    Lam, D.
    Wang, X.
    Gong, J.
    Kapsalis, S.
    Hickman, D.
    Zhang, V.
    Winkler, T.
    Wu, B.
    Vyas, P.
    ANNALS OF HEMATOLOGY, 2019, 98 : S40 - S41
  • [37] Ivosidenib (IVO; AG-120) in IDH1-mutant newly-diagnosed acute myeloid leukemia (ND AML): Updated results from a phase 1 study.
    Roboz, Gail J.
    Dinardo, Courtney Denton
    Stein, Eytan M.
    de Botton, Stephane
    Mims, Alice S.
    Prince, Gabrielle T.
    Altman, Jessica K.
    Arellano, Martha Lucia
    Erba, Harry Paul
    Pollyea, Daniel Aaron
    Stein, Anthony Selwyn
    Watts, Justin M.
    Fathi, Amir Tahmasb
    Kantarjian, Hagop M.
    Tallman, Martin S.
    Fan, Bin
    Liu, Hua
    Wu, Bin
    Attar, Eyal C.
    Stone, Richard M.
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [38] Phase 1 study of AG-881, an inhibitor of mutant IDH1/IDH2, in patients with advanced IDH-mutant solid tumors, including glioma
    Mellinghoff, Ingo K.
    Penas-Prado, Marta
    Peters, Katherine B.
    Cloughesy, Timothy Francis
    Burris, Howard A.
    Maher, Elizabeth A.
    Janku, Filip
    Cote, Gregory Michael
    De La Fuente, Macarena Ines
    Clarke, Jennifer
    Steelman, Lori
    Le, Kha
    Zhang, Yanwei
    Sonderfan, Alison
    Hummel, Diana
    Schoenfeld, Steven
    Yen, Katharine
    Pandya, Shuchi Sumant
    Wen, Patrick Y.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [39] ClarIDHy: A phase 3 multicenter randomized double-blind study of AG-120 versus placebo in patients with non-resectable or metastatic cholangiocarcinoma with an IDH1 mutation.
    Abou-Alfa, Ghassan K.
    Valle, Juan W.
    Kelley, Robin Kate
    Goyal, Lipika
    Shroff, Rachna T.
    Javle, Milind M.
    Borad, Mitesh J.
    Cleary, James M.
    El-Khoueiry, Anthony B.
    Bendell, Johanna C.
    Macarulla, Teresa Mercade
    Vogel, Arndt
    Korth, Christopher
    Jiang, Liewen
    Gliser, Camelia
    Bin Wu
    Agresta, Samuel V.
    Pandya, Shuchi Sumant
    Zhu, Andrew X.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (04)
  • [40] A PHASE 1, OPEN-LABEL, PERIOPERATIVE STUDY OF IVOSIDENIB (AG-120) AND VORASIDENIB (AG-881) IN RECURRENT, IDH1-MUTANT, LOW-GRADE GLIOMA: RESULTS FROM COHORT 1
    Mellinghoff, I. K.
    Wen, P. Y.
    Taylor, J. W.
    Maher, E. A.
    Arrillaga-Romany, I.
    Peters, K. B.
    Le, K.
    Tai, F.
    Steelman, L.
    Cloughesy, T. F.
    NEURO-ONCOLOGY, 2019, 21 : 2 - 2
12345